AOD-9604
Lipolytic GH Fragment
AOD-9604 is the C-terminal fragment of human growth hormone (residues 177–191), engineered to retain GH's fat-metabolizing properties while eliminating its effects on insulin sensitivity and IGF-1 — a clean lipolytic tool without the metabolic side effects of full GH.
At a Glance
Full growth hormone affects fat metabolism, muscle growth, IGF-1 production, and insulin sensitivity simultaneously. AOD-9604 isolates the lipolytic fragment responsible for fat breakdown — binding the GH receptor's fat-specific domain without triggering the full receptor cascade.
Phase 2 trials in obese humans showed modest but statistically significant fat loss versus placebo. Its favorable safety profile and non-diabetogenic action set it apart from full GH and other metabolic compounds in research contexts.
Research interest has expanded beyond simple fat loss to include cartilage repair, where GH receptor signaling in chondrocytes appears relevant — adding an unexpected secondary research dimension.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
Beta-3 Adrenergic Stimulation
Stimulates beta-3 adrenergic receptors in adipose tissue to drive lipolysis — fat cell breakdown and free fatty acid release into circulation.
No IGF-1 Elevation
Unlike full GH, AOD-9604 does not stimulate IGF-1 production — isolating the lipolytic mechanism from GH's anabolic downstream effects.
Non-Diabetogenic
Does not affect insulin sensitivity or glucose metabolism — a key safety advantage over full GH administration in metabolic research.
Cartilage Research
Emerging evidence for chondroprotective and cartilage repair effects via GH receptor signaling in joint tissue — an unexpected secondary research area.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Visceral and subcutaneous fat reduction — Phase 2 human trial data
- Lipolysis mechanism research — beta-3 adrenergic pathway in adipose tissue
- GH fragment comparison studies — isolating fat metabolism from full GH cascade
- Cartilage protection and repair — chondroprotective effects in joint models
- Obesity research without diabetogenic risk — useful in insulin-sensitive populations
- Body composition — fat mass reduction without muscle loss or IGF-1 elevation
- Combination with GLP-1 agonists for additive fat metabolism research
AOD-9604's clean lipolytic profile — fat loss without IGF-1 or insulin effects — makes it a precision tool for mechanistic fat metabolism research.
AOD-9604 occupies a unique niche — GH-derived lipolysis without GH's anabolic or metabolic side effects.
| Aspect | AOD-9604 | Full GH | Semaglutide |
|---|---|---|---|
| Fat Loss | Direct lipolysis (beta-3) | Yes (via GH receptor) | Appetite + lipolysis |
| IGF-1 Effect | None | Significant elevation | None |
| Insulin Sensitivity | Unaffected | May reduce | Improved |
| Anabolic Effect | None | Significant | None |
| Best Research Use | Isolated lipolysis | Full GH axis | Appetite + metabolic |
The following reflects findings from published preclinical and clinical safety assessments where available.
No IGF-1 or insulin effects — clean lipolytic mechanism in isolation
Phase 2 human data — fat loss vs placebo confirmed in clinical trials
Favorable safety profile — TGA-approved as food ingredient in Australia (GRAS status)
Modest effect size — Phase 2 fat loss statistically significant but not as dramatic as GLP-1 agonists
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026